Roche - Announced Jan 2009, upfront payment ~$1.0 Million, Milestone payment $XX,000,000 circa July 2011 + royalties on any successful drugs developed as a result.
MedImmune - Announced Aug 2010, upfront payment ~$1.5 Million, Milestone payment $98,000,000 circa Aug 2011 + royalties on any successful drugs developed as a result.
Rumoured deal? - might be announced < 3 months, similar arrangement as above.
Essentially if PYC can successfully get a Milestone payment out of one of these 2, potential 3 companies it will put a rocket under the share price.
Doing the maths (correct me if I'm wrong), if, in the next 12 months MedImmune makes the payment of $98,000,000 to PYC, based purely on cash value, PYC would be valued at 35 cents (98m / 283m shares) or approximately 6x its value. However at those levels if would be a potential takeover target with a Value of $200 - $400 m or 12x ($0.70) � 23x ($1.40) its current share price.
PYC Price at posting:
5.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)